130477-52-0
中文名称
130477-52-0
英文名称
L-655,708
CAS
130477-52-0
分子式
C18H19N3O4
分子量
341.36
MOL 文件
130477-52-0.mol
更新日期
2024/05/30 16:02:10
130477-52-0 结构式
基本信息
中文别名
(S)-7-甲氧基-9-氧代-11,12,13,13A-四氢-9H-9H-咪唑并[1,5-A]吡咯并[2,1-C][1,4]苯二氮-1-羧酸乙酯 英文别名
MSDL-655,708
ETHYL (S)-11,12,13,13A-TETRAHYDRO-7-METHOXY-9-OXO-9H-IMIDAZO[1,5-A]PYRROLO[2,1-C][1,4]BENZODIAZEPINE-1-CARBOXYLATE
Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate
11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1.5-a]pyrrolo[2.1-c][1.4]benzodiazepine-1-carboxylicacidethylester
(S)-ethyl 7-methoxy-9-oxo-11,12,13,13a- tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate
11,12,13,13A-TETRAHYDRO-7-METHOXY-9-OXO-9H-IMIDAZO[1,5-A]PYRROLO[2,1-C][1,4]BENZODIAZEPINE-1-CARBOXYLIC ACID, ETHYL ESTER
9H-IMidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid, 11,12,13,13a-tetrahydro-7-Methoxy-9-oxo-, ethyl ester, (13aS)-
9H-IMidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid, 11,12,13,13a-tetrahydro-7-Methoxy-9-oxo-, ethyl ester, (13aS)- (011-14426_500Mg)
物理化学性质
熔点175-176 °C
沸点584.4±50.0 °C(Predicted)
密度1.42±0.1 g/cm3(Predicted)
储存条件Desiccate at +4°C
溶解度DMSO: 6 mg/mL
溶解度二甲基亚砜：6 mg/毫升
酸度系数(pKa)1.49±0.20(Predicted)
形态powder
130477-52-0价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-14426 | 130477-52-0 L-655708 | 130477-52-0 | 5mg | 880元 |
| 2024/04/30 | HY-14426 | 130477-52-0 L-655708 | 130477-52-0 | 10mM * 1mLin DMSO | 968元 |
| 2024/04/30 | HY-14426 | 130477-52-0 L-655708 | 130477-52-0 | 10mg | 1550元 |
常见问题列表
生物活性
L-655708 是有效的, 选择性 GABAA 受体反向激动剂 (Ki=0.45 nM)。体外研究
L655708 is a potent, selective inverse agonist for the benzodiazepine site of GABAA receptors containing the α5 subunit (Ki = 0.45 nM). Displays 50-100-fold selectivity over GABAA receptors containing α1, α2, α3 orα6 subunits in combination with β3 and γ2. Enhances LTP in a mouse hippocampal slice model and increases spatial learning, without displaying proconvulsant activity.
体内研究
L-655708 at 0.7 mg/kg, administered intraperitoneally, would result in 60-70% occupancy of α5 GABAA receptors with limited binding to α1, α2, and α3 subunit-containing GABAA receptors and no significant off-target behavioral effects, such as sedation and motor impairment.